IRS1 and cancer: In other cancer types, this is associated with inhibitory phosphorylation of the signaling adapter, insulin receptor substrate-1 (IRS-1) and inhibition of the downstream PI3K/Akt/mTOR and mitogen-activated protein-kinase/extracellular signal-regulated kinase (MAPK/ERK) pathways (92–94).